Literature DB >> 19132008

Do 'basal-like' breast cancers really exist?

Barry Gusterson1.   

Abstract

It has been proposed that gene expression profiles will revolutionize the classification of breast cancer, eventually replacing histopathology with a more reproducible technology. These new approaches, combined with a better understanding of the cellular origins of breast cancer, should enable us to identify patient subgroups for more effective therapy. However, in such a rapidly advancing field it is essential that initial and thought-provoking results do not become established as 'facts' without question. This Opinion addresses some of the negatives and positives generated by the term 'basal-like' breast cancer, and questions its existence as an entity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19132008     DOI: 10.1038/nrc2571

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  61 in total

1.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

2.  The development of epithelial phenotypes in the human fetal and infant breast.

Authors:  R Anbazhagan; P P Osin; J Bartkova; B Nathan; E B Lane; B A Gusterson
Journal:  J Pathol       Date:  1998-02       Impact factor: 7.996

Review 3.  National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.

Authors: 
Journal:  J Natl Cancer Inst Monogr       Date:  2001

4.  Identification of a basal-like subtype of breast ductal carcinoma in situ.

Authors:  Chad A Livasy; Charles M Perou; Gamze Karaca; David W Cowan; Diane Maia; Susan Jackson; Chiu-Kit Tse; Sarah Nyante; Robert C Millikan
Journal:  Hum Pathol       Date:  2007-02       Impact factor: 3.466

5.  Steroid hormone receptor status of mouse mammary stem cells.

Authors:  Marie-Liesse Asselin-Labat; Mark Shackleton; John Stingl; François Vaillant; Natasha C Forrest; Connie J Eaves; Jane E Visvader; Geoffrey J Lindeman
Journal:  J Natl Cancer Inst       Date:  2006-07-19       Impact factor: 13.506

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 7.  BRCA1 functions as a breast stem cell regulator.

Authors:  W D Foulkes
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

8.  Breast cancer special types: why bother?

Authors:  J S Reis-Filho; S R Lakhani
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

9.  Expression of BRCA1 protein in breast cancer and its prognostic significance.

Authors:  Emad A Rakha; Somaia E El-Sheikh; Mona A Kandil; Maysa E El-Sayed; Andrew R Green; Ian O Ellis
Journal:  Hum Pathol       Date:  2008-04-08       Impact factor: 3.466

10.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Authors:  Tan A Ince; Andrea L Richardson; George W Bell; Maki Saitoh; Samuel Godar; Antoine E Karnoub; James D Iglehart; Robert A Weinberg
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  57 in total

Review 1.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

2.  Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Authors:  Marco Colleoni; Bernard F Cole; Giuseppe Viale; Meredith M Regan; Karen N Price; Eugenio Maiorano; Mauro G Mastropasqua; Diana Crivellari; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Barry A Gusterson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

Review 3.  Murine mammary epithelial stem cells: discovery, function, and current status.

Authors:  Jane E Visvader; Gilbert H Smith
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

Review 4.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 5.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis.

Authors:  Jane E Visvader
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

6.  Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy.

Authors:  Sandro Santagata; Tan A Ince
Journal:  Expert Rev Anticancer Ther       Date:  2014-09-27       Impact factor: 4.512

Review 7.  SLUG: Critical regulator of epithelial cell identity in breast development and cancer.

Authors:  Sarah Phillips; Charlotte Kuperwasser
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

8.  Taxonomy of breast cancer based on normal cell phenotype predicts outcome.

Authors:  Sandro Santagata; Ankita Thakkar; Ayse Ergonul; Bin Wang; Terri Woo; Rong Hu; J Chuck Harrell; George McNamara; Matthew Schwede; Aedin C Culhane; David Kindelberger; Scott Rodig; Andrea Richardson; Stuart J Schnitt; Rulla M Tamimi; Tan A Ince
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

9.  At last: classification of human mammary cells elucidates breast cancer origins.

Authors:  Robert D Cardiff; Alexander D Borowsky
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 10.  [Translational research and diagnostics for breast cancer].

Authors:  H H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.